Detailed Product Description

 

Weight Loss Fat Loss Hormones Drug Rimonabant CAS 168273-06-1 for Reduceing Weight
 
Quick Details

 

 
Rimonabant Description
 
(1) Rimonabant hydrochloride (SR-141716A) is a potent and selective CB1 cannabinoid inverse agonist/antagonist with a Ki of 1.6 nM, minimal affinity for CB2, and and some GPR55 agonist activity.
 
Rimonabant was developed as an anti-obesity drug because of its appetite suppressant activity, but was taken off the market because of side effects of depression and anxiety.
 
(2) Under development by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity.
 
(3) It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the most advanced endocannabinoid receptor antagonist in clinical development and offers a novel therapeutic approach to appetite control and weight reduction.
 
Rimonabant Application
 
Rimonabant is a weight loss drug, Sanofi-Aventis by the French company successfully developed for the treatment of obesity is the first cannabinoid type 1 receptor (CB1) antagonist, by selectively blocking the EC system cannabis Su -1 (cannabinoid-1, CB1) receptors play a role, can significantly reduce weight, reduce waist circumference, reducing risk factors for cardiovascular disease, but also can improve blood lipids and insulin resistance and metabolic syndrome, especially for the existence of clinical obesity or heart disease risk for people.
 
Rimonabant may also be found to be effective in assisting some smokers to quit smoking.Sanofi is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) program involves more than 6,000 subjects.
 
STRATUS is designed to explore two smoking-related therapies: first, to use rimonabant directly to aid in smoking cessation; second, to help prevent weight gain in former smokers. Initial results apparently suggest rimonabant is effective for both uses. However, the FDA has explicitly stated to Sanofi that, without additional studies, rimonabant cannot be approved in the United States for smoking cessation therapy.

COA

 

 
What is Weight Loss Steroids Rimonabant (Acomplia) Used for?
 
Acomplia was studied to be used complementary to diet and exercise to treat obese or overweight patients who suffer from type 2 diabetes and abnormal levels of fat in the blood.
 
Sanofi argued that Acomplia could also prevent the risk of cardiovascular disease. Patients with large waist circumference (102 cm in men and 88 cm in women) were said to most benefit from taking the drug.
 
Rimonabant was submitted to the Food and Drug Administration (FDA) for approval in the United States. However, in 2007, the FDA's Endocrine and Metabolic Drugs Advisory Committee (EMDAC) concluded the French manufacturer Sanofi-Aventis failed to demonstrate the safety of rimonabant and voted against recommending the anti-obesity treatment for approval. Subsequently, Sanofi-Aventis announced it was suspending the new drug application (NDA) for rimonabant, and that it would resubmit an application at some point in the future.
 
Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) program involves more than 6,000 subjects. STRATUS is designed to explore two smoking-related therapies: first, to use rimonabant directly to aid in smoking cessation; second, to help prevent weight gain in former smokers. Initial results apparently suggest rimonabant is effective for both uses. However, the FDA has explicitly stated to Sanofi that, without additional studies, rimonabant cannot be approved in the United States for smoking cessation therapy. According to a Cochrane Collaboration review in 2007, rimonabant "may increase the odds of quitting approximately 11/2-fold".
 
Related product
 

 

Detailed Product Description

 

Weight Loss Fat Loss Hormones Drug Rimonabant CAS 168273-06-1 for Reduceing Weight
 
Quick Details

 

 
Rimonabant Description
 
(1) Rimonabant hydrochloride (SR-141716A) is a potent and selective CB1 cannabinoid inverse agonist/antagonist with a Ki of 1.6 nM, minimal affinity for CB2, and and some GPR55 agonist activity.
 
Rimonabant was developed as an anti-obesity drug because of its appetite suppressant activity, but was taken off the market because of side effects of depression and anxiety.
 
(2) Under development by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity.
 
(3) It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the most advanced endocannabinoid receptor antagonist in clinical development and offers a novel therapeutic approach to appetite control and weight reduction.
 
Rimonabant Application
 
Rimonabant is a weight loss drug, Sanofi-Aventis by the French company successfully developed for the treatment of obesity is the first cannabinoid type 1 receptor (CB1) antagonist, by selectively blocking the EC system cannabis Su -1 (cannabinoid-1, CB1) receptors play a role, can significantly reduce weight, reduce waist circumference, reducing risk factors for cardiovascular disease, but also can improve blood lipids and insulin resistance and metabolic syndrome, especially for the existence of clinical obesity or heart disease risk for people.
 
Rimonabant may also be found to be effective in assisting some smokers to quit smoking.Sanofi is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) program involves more than 6,000 subjects.
 
STRATUS is designed to explore two smoking-related therapies: first, to use rimonabant directly to aid in smoking cessation; second, to help prevent weight gain in former smokers. Initial results apparently suggest rimonabant is effective for both uses. However, the FDA has explicitly stated to Sanofi that, without additional studies, rimonabant cannot be approved in the United States for smoking cessation therapy.

COA

 

 
What is Weight Loss Steroids Rimonabant (Acomplia) Used for?
 
Acomplia was studied to be used complementary to diet and exercise to treat obese or overweight patients who suffer from type 2 diabetes and abnormal levels of fat in the blood.
 
Sanofi argued that Acomplia could also prevent the risk of cardiovascular disease. Patients with large waist circumference (102 cm in men and 88 cm in women) were said to most benefit from taking the drug.
 
Rimonabant was submitted to the Food and Drug Administration (FDA) for approval in the United States. However, in 2007, the FDA's Endocrine and Metabolic Drugs Advisory Committee (EMDAC) concluded the French manufacturer Sanofi-Aventis failed to demonstrate the safety of rimonabant and voted against recommending the anti-obesity treatment for approval. Subsequently, Sanofi-Aventis announced it was suspending the new drug application (NDA) for rimonabant, and that it would resubmit an application at some point in the future.
 
Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) program involves more than 6,000 subjects. STRATUS is designed to explore two smoking-related therapies: first, to use rimonabant directly to aid in smoking cessation; second, to help prevent weight gain in former smokers. Initial results apparently suggest rimonabant is effective for both uses. However, the FDA has explicitly stated to Sanofi that, without additional studies, rimonabant cannot be approved in the United States for smoking cessation therapy. According to a Cochrane Collaboration review in 2007, rimonabant "may increase the odds of quitting approximately 11/2-fold".
 
Related product
 

Hydrogen Inhalation Machine

Hot Sale Portable Household Spe Pem Electrolysis Gas Hydrogen Breathing Inhalation Device Pure Water Electrolyzer Hydrogen Production Generator

Japanese Hydrogen Inhaler,Water Electrolysis Hydrogen Generator,Hydrogen Production Machine,Brown Gas Generator,Hydrogen Inhalation Machine

A hydrogen inhaler is a device that delivers hydrogen gas for inhalation. Hydrogen gas is considered to have potential health benefits due to its antioxidant and anti-inflammatory properties. The inhaler typically contains a chamber that generates hydrogen gas by electrolysis of water or by using hydrogen-rich tablets or cartridges. When the user inhales through the device, they can potentially benefit from the therapeutic effects of hydrogen gas. Some claimed benefits of hydrogen inhalation include reducing oxidative stress, inflammation, and improving athletic performance. However, further research is needed to fully understand the potential benefits and risks associated with hydrogen inhalation. It is important to consult a healthcare professional before using any new health device or treatment.

What Is Hydrogen?
1. Hydrogen is a chemical element, the first on the periodic table.

1. Reduce oxidative damage

Japanese Hydrogen Inhaler,Water Electrolysis Hydrogen Generator,Hydrogen Production Machine,Brown Gas Generator,Hydrogen Inhalation Machine

Shenzhen Guangyang Zhongkang Technology Co., Ltd. , https://www.nirlighttherapy.com